Cargando…
Encoding the Sequence of Specific Autoantibodies Against beta-Amyloid and alpha-Synuclein in Neurodegenerative Diseases
There is no effective disease-modifying therapy for Alzheimer's or Parkinson's disease. As pathological hallmarks, the specific peptide amyloid-β and the specific protein α-Synuclein aggregate and deposit in and destabilize neurons, which lead to their degeneration. Within the context of a...
Autores principales: | Albus, Alexandra, Jördens, Marit, Möller, Moritz, Dodel, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718452/ https://www.ncbi.nlm.nih.gov/pubmed/31507618 http://dx.doi.org/10.3389/fimmu.2019.02033 |
Ejemplares similares
-
Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein
por: Albus, Alexandra, et al.
Publicado: (2018) -
Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective
por: Knecht, Luisa, et al.
Publicado: (2022) -
Revisiting the Impact of Neurodegenerative Proteins in Epilepsy: Focus on Alpha-Synuclein, Beta-Amyloid, and Tau
por: Paudel, Yam Nath, et al.
Publicado: (2020) -
Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson’s Disease: Sources of (Error) Variance in Biomarker Assays
por: Heinzel, Sebastian, et al.
Publicado: (2014) -
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro
por: Köppen, Janett, et al.
Publicado: (2020)